See more : Valeura Energy Inc. (VLU.L) Income Statement Analysis – Financial Results
Complete financial analysis of Pulse Biosciences, Inc. (PLSE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pulse Biosciences, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Delhivery Limited (DELHIVERY.BO) Income Statement Analysis – Financial Results
- Acri Capital Acquisition Corporation (ACACW) Income Statement Analysis – Financial Results
- PayPal Holdings, Inc. (PYPL.NE) Income Statement Analysis – Financial Results
- Changshu Fengfan Power Equipment Co., Ltd. (601700.SS) Income Statement Analysis – Financial Results
- Handelsinvest Offensiv 80 (AK) (HAIOF80A.CO) Income Statement Analysis – Financial Results
Pulse Biosciences, Inc. (PLSE)
Industry: Medical - Instruments & Supplies
Sector: Healthcare
Website: https://www.pulsebiosciences.com
About Pulse Biosciences, Inc.
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 700.00K | 1.42M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.21M | 11.94M | 1.97M | 665.00K | 666.00K | 665.00K | 665.00K | 665.00K | 0.00 | 0.00 |
| Gross Profit | -1.21M | -11.24M | -550.00K | -665.00K | -666.00K | -665.00K | -665.00K | -665.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | -1,606.29% | -38.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 27.80M | 20.84M | 28.64M | 26.44M | 24.96M | 17.25M | 9.65M | 5.99M | 2.58M | 44.57K |
| General & Administrative | 15.78M | 13.96M | 19.07M | 22.86M | 22.33M | 20.05M | 15.50M | 2.93M | 1.22M | 73.71K |
| Selling & Marketing | 0.00 | 12.02M | 14.75M | 7.26M | 5.86M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.78M | 25.97M | 33.82M | 22.86M | 22.33M | 20.05M | 15.50M | 2.93M | 1.22M | 73.71K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 665.00K | 666.00K | -28.00K | 665.00K | 665.00K | 665.39K | 0.00 |
| Operating Expenses | 43.57M | 46.81M | 62.46M | 49.97M | 47.95M | 37.96M | 25.81M | 9.59M | 4.47M | 514.29K |
| Cost & Expenses | 43.57M | 58.76M | 64.43M | 49.97M | 47.95M | 37.96M | 25.81M | 9.59M | 4.47M | 514.29K |
| Interest Income | 0.00 | 263.00K | 646.00K | 114.00K | 983.00K | 446.00K | 247.00K | 68.00K | 0.00 | 0.00 |
| Interest Expense | 1.36M | 448.00K | 646.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.21M | 1.36M | 1.15M | 1.10M | 1.16M | 1.31M | 1.00M | 759.00K | 716.98K | 200.57K |
| EBITDA | -42.37M | -56.70M | -61.87M | -48.87M | -46.79M | -36.65M | -24.57M | -8.83M | -3.75M | -108.00K |
| EBITDA Ratio | 0.00% | -8,293.86% | -4,443.86% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -43.57M | -58.06M | -63.01M | -49.97M | -47.95M | -37.96M | -25.81M | -9.59M | -4.47M | -308.57K |
| Operating Income Ratio | 0.00% | -8,293.86% | -4,443.86% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.36M | -448.00K | -646.00K | 114.00K | 983.00K | 418.00K | 247.00K | 68.00K | 0.00 | -396.00K |
| Income Before Tax | -42.21M | -58.51M | -63.66M | -49.85M | -46.97M | -37.55M | -25.57M | -9.52M | -4.47M | -514.29K |
| Income Before Tax Ratio | 0.00% | -8,357.86% | -4,489.42% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 448.00K | -500.00K | -114.00K | -983.00K | -28.00K | -912.00K | -94.00K | -1.66M | 39.43K |
| Net Income | -42.21M | -58.95M | -63.16M | -49.74M | -45.99M | -37.55M | -25.57M | -9.52M | -2.81M | -474.86K |
| Net Income Ratio | 0.00% | -8,421.86% | -4,454.16% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.88 | -1.74 | -2.26 | -2.14 | -2.22 | -2.20 | -1.73 | -0.86 | -0.37 | -0.19 |
| EPS Diluted | -0.88 | -1.74 | -2.26 | -2.14 | -2.22 | -2.20 | -1.73 | -0.86 | -0.37 | -0.19 |
| Weighted Avg Shares Out | 48.04M | 33.94M | 27.96M | 23.25M | 20.75M | 17.08M | 14.75M | 11.01M | 7.57M | 2.51M |
| Weighted Avg Shares Out (Dil) | 48.04M | 33.94M | 27.96M | 23.25M | 20.75M | 17.08M | 14.75M | 11.01M | 7.57M | 2.51M |
Pulse Biosciences Reports Fourth Quarter & Full Year 2021 Financial Results
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced financial results for the fourth quarter and full year of 2021. Company Updates Implemented changes to...
Pulse Biosciences Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call for March 31, 2022
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the fourth quarter and full year of 2021 after market...
Pulse Biosciences (PLSE) Stock: Why The Price Significantly Fell
The stock price of Pulse Biosciences Inc (NASDAQ: PLSE) fell by 34.44% in the most recent trading session. This is why it happened.
Pulse Biosciences, Inc (PLSE)'s Technical Outlook is Bright After Key Golden Cross
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Pulse Biosciences, Inc. (PLSE) CEO Darrin Uecker on Q3 2021 Results - Earnings Call Transcript
Pulse Biosciences, Inc. (PLSE) CEO Darrin Uecker on Q3 2021 Results - Earnings Call Transcript
Pulse Biosciences Schedules Third Quarter 2021 Financial Results Conference Call for November 15, 2021
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the third quarter of 2021 after market close on Monday, November 15, 2021. Company management...
Pulse Biosciences, Inc. (PLSE) CEO Darrin Uecker on Q2 2021 Results - Earnings Call Transcript
Pulse Biosciences, Inc. (PLSE) CEO Darrin Uecker on Q2 2021 Results - Earnings Call Transcript
Pulse Biosciences Schedules Second Quarter 2021 Financial Results Conference Call for August 9, 2021
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the second quarter of 2021 after market close on Monday, August 9, 2021. Company management...
Why Pulse Biosciences Stock Moved Higher Thursday
The medical technology company got rid of $41.6 million in debt with a large private sale of stock on Thursday.
Pulse Biosciences Stock Is Trading Higher After Company's Chairman Agrees To Buy Shares Worth $50M
Pulse Biosciences Inc's (NASDAQ: PLSE) Board Chairman, Robert W. Duggan, will purchase 3.04 million common shares at $16.40 per share in a private placement.
Source: https://incomestatements.info
Category: Stock Reports